A recent study highlighted the challenges of managing blood pressure in patients with lymphoid malignancies who are being treated with Bruton’s tyrosine kinase inhibitors. The study revealed that these inhibitors can lead to fluctuations in blood pressure and require close monitoring and management. The findings emphasize the importance of assessing and addressing hypertension in patients undergoing this type of treatment to ensure their overall well-being. The study sheds light on the complexities involved in managing blood pressure in patients with lymphoid malignancies receiving this specific type of therapy.
Source link
Study Unveils Complexities of BP Management with Bruton’s Tyrosine Kinase Inhibitors in Lymphoid Malignancies
